What Happened?
Framingham, MA-based Berg Pharma has Appointed Niven R Narain as Chief Technology Officer
About the Company
Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.
About the Person
Niven R. Narain is Co-founder, President and Chief Technology Officer of Berg Pharma (formerly Cytotech Labs), a vertically integrated healthcare solutions company that houses the Interrogative Biology™ discovery platform that arbitrates leading-edge discovery and health analytics initiatives. Niven also co-founded Berg Biosystems and Berg Diagnostics which are now integrated as divisions of Berg Pharma. Most notably, Niven is the inventor of the Berg Interrogative Biology™ Discovery platform that serves as the engine of innovation driving rapid identification of therapeutic targets and biomarkers for diagnostic development, and produced 6 IND's in less than 4 years among numerous validated biomarker panels in cancer and drug toxicity. He is also the discoverer of a novel cancer technology, BPM 31510 going into Phase III trials for skin cancers and currently in late Phase I trials indicated for solid tumors and heme malignancies. Narain has over 325 US and international issued and pending patents that cover technologies pertaining to drug discovery platforms, cancer, wound healing, pain, fatigue, burns, diabetes, chemotoxicity, metabolic diseases, and corresponding diagnostics of the aforementioned. He oversees academic/government collaborations that include the Harvard Medical School, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cornell Weill, Mt. Sinai School of Medicine, UCLA, and the CPDR/DoD among international collaborations in Europe. Narain is a Distinguished Research Scholar at the Miller School of Medicine in Miami and serves as Senior Biopharmaceutical Advisor to Ocean Tomo in Chicago, the leading Intellectual Capital Merchant Banc. Prior to moving to Boston, Narain was the Director of Cutaneous Oncology & Therapeutics Research at the University of Miami Miller School of Medicine from 2005-2009 where he specialized in translational research in cancer and wound healing. Narain has published and presented his research at international medical and scientific meetings and has been key in securing funding in both the academic and industry levels. Significant media coverage on the cancer discovery has been featured globally on subsidiaries of CNN, NBC, FOX, ABC, and TV Asia. He is the recipient of the prestigious Charles Lacaillade Memorial Research Prize (St. John's University, NY), Charles Gordon Zubrod Cancer Prize (UM/Sylvester Cancer Center, FL), and an Award of Excellence (National Institutes of Health/NIDDK). Active in community outreach, he has served as a mentor to many high school, undergraduate, and graduate students in addition to clinical fellows and residents in the Upward Bound, Intel Science Program, NIH programs, and the Howard Hughes Medical Internship (HHMI). Narain served on the Congregational Council for Christ the King Lutheran Church in Miami and currently is an active member at the Trinity Church Boston. He is an Alumni Advisor to St. John's University, NY. Narain received his pre-medical education at St. John's, NY earning BS/BA in Biochemistry and Philosophy. He received his clinical dermatology research and PhD training in cancer biology at the Miller School of Medicine, University of Miami. Narain is member of numerous national and international oncology and dermatology academic and pharmaceutical societies and associations. Most passionate about innovation that drives patient care and positive changes in the health ecosystem, Niven was an invited speaker at the Aspen Ideas Festival to offer his perspective on cancer in addition to an international symposium on innovation at the World Intellectual Property Organization in Geneva.
Info Source
News
Short Profile